Loading...

Mirati Therapeutics, Inc.

MRTXNASDAQ
Healthcare
Biotechnology
$58.70
$-0.10(-0.17%)

Mirati Therapeutics, Inc. (MRTX) Company Profile & Overview

Explore Mirati Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Mirati Therapeutics, Inc. (MRTX) Company Profile & Overview

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

SectorHealthcare
IndustryBiotechnology
CEOCharles M. Baum

Contact Information

858 332 3410
3545 Cray Court, San Diego, CA, 92121

Company Facts

587 Employees
IPO DateJul 15, 2013
CountryUS

Frequently Asked Questions

;